San Diego, California – May 17, 2026
Nabsys 2.0 announced the expansion of its OhmX™ electronic genome mapping (EGM) platform through new installations under the Hitachi High-Tech America (HTA) RAMP UP Program, strengthening translational research efforts in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The initiative includes collaboration with renowned cytogeneticist Brynn Levy from Columbia University Vagelos College of Physicians and Surgeons. The partnership aims to accelerate research applications using high-resolution genome mapping technologies to better characterize structural genomic abnormalities associated with hematologic cancers. Nabsys stated that the program is designed to address major limitations in traditional cytogenetic testing workflows while supporting broader adoption of advanced genomic analysis in cancer research laboratories.
OhmX Platform Designed to Improve Structural Variant Detection
The OhmX Platform uses proprietary electronic genome mapping technology combined with nanofluidics and computational biology to analyze ultra-long DNA molecules with high precision. Current cytogenetic methods such as fluorescence in situ hybridization (FISH) and karyotyping are often limited either by narrow genomic targeting or lower structural resolution. Genome-wide sequencing technologies can provide broader analysis, but they frequently involve higher operational complexity and costs. According to Nabsys, the OhmX system was developed to bridge these gaps by delivering high-resolution structural variant (SV) and copy number variation (CNV) analysis in a compact and cost-effective format suitable for research laboratories of varying sizes.
The collaboration with Dr. Levy’s laboratory will initially focus on genomic regions linked to AML and MDS, diseases where chromosomal abnormalities and structural variations strongly influence disease progression and treatment response. Researchers aim to use EGM technology to provide more comprehensive characterization of leukemia-associated genomic changes while integrating these insights into existing cytogenetic workflows. Nabsys believes the platform’s long-read DNA analysis capabilities may significantly improve the ability to study complex genomic rearrangements that are difficult to detect using conventional methods.
RAMP UP Program Expands Translational Genomics Applications
The RAMP UP Program was established by Nabsys and Hitachi High-Tech America to place OhmX systems in leading research institutions and generate real-world translational data supporting the development of new EGM applications. Multiple OhmX systems have now been installed in Dr. Levy’s laboratory under a sponsored research agreement focused on hematologic malignancies. The companies said the initiative is expected to help researchers investigate clinically relevant genomic loci involved in leukemia biology while simplifying workflows compared with traditional genome-wide technologies.
Advertisement
Nabsys Founder and CEO Barrett Bready emphasized that structural variation remains one of the most critical yet underexplored areas in cancer genomics research. He stated that collaboration with leading cytogenetics experts is essential for demonstrating how EGM technology can be applied to real-world research questions in AML and related blood cancers. Dr. Levy also noted that accessible next-generation tools capable of generating high-resolution genomic insights could enable entirely new translational research approaches for hematologic malignancies. The company believes these efforts may contribute to future advances in precision oncology and molecular diagnostics.
Focus on Accessibility and Advanced Genome Mapping
Nabsys highlighted that the OhmX Platform was specifically developed to reduce the cost and complexity associated with advanced structural genomic analysis. The platform supports detailed investigation of chromosomal abnormalities using a less labor-intensive workflow, potentially increasing accessibility for research institutions seeking comprehensive genomic insights without large-scale infrastructure requirements. In AML and MDS, where structural genomic abnormalities drive disease biology, the ability to combine structural variation analysis with copy number data could provide a more complete genomic profile for translational studies and future therapeutic research. HTA President and CEO Brian Buckingham stated that there remains significant demand for technologies capable of supporting more targeted and personalized approaches in hematologic cancer research.
He added that the OhmX Platform’s high-resolution mapping and long-read capabilities may help researchers gain deeper insight into leukemia-associated genomic changes. Nabsys also confirmed participation at the American Cytogenetics Conference 2026, where the company plans to present ongoing research applications involving electronic genome mapping, including CRISPR-assisted genomic analysis. The OhmX Platform is currently available worldwide for research-use-only applications.
Source: Nabsys press release
